Evolus (EOLS) Company Report

Evolus is experiencing strong initial success with its second product, Evolysse, an HA filler, which is exceeding the launch trajectory of other recent HA products.
The company projects achieving profitability in Q4 2025 and for the full year 2026, supported by a $25 million reduction in expenses.
Evolus has access to $100 million in term loan capacity for business development and a $40 million revolving line of credit.
Despite a challenging macroeconomic environment affecting the aesthetic market, particularly fillers, Evolus's Jeuveau continues to grow in the U.S., and its international business shows robust growth.
The company plans to introduce its flagship sculpt product, Skulpt, for the mid-face in the second half of 2026, further expanding its portfolio.

Nov 11, 2025, 4:20 PM

Transcript

Evolus Reports Q3 2025 Results and Reaffirms Full-Year Guidance

EOLS

Earnings

Guidance Update

Product Launch

Evolus reported Q3 2025 net revenue of $69.0 million, representing a 13% year-over-year increase.
The company reaffirmed its full-year 2025 total net revenue guidance of $295 million to $305 million, with Evolysse™ injectable HA gels expected to contribute 10% to 12% of this total.
Evolus anticipates achieving non-GAAP operating income of $5 million to $7 million in Q4 2025 and projects annual profitability beginning in 2026. The Evolysse™ launch generated $5.7 million in revenue for Q3 2025 and $15.5 million year-to-date.

Nov 5, 2025, 9:30 PM

Presentation

Evolus Reports Q3 2025 Results and Reiterates 2025 Guidance

EOLS

Earnings

Guidance Update

Product Launch

Evolus reported Q3 2025 global net revenue of $69 million, a 13% increase over 2024, with Jeuveau contributing $63.2 million and Evolisse $5.7 million.
The company achieved a non-GAAP operating loss of $3.1 million in Q3 2025, an improvement from $6.7 million in Q3 2024, and reported a gross margin of 66.5%.
Evolus reiterated its full-year 2025 net revenue guidance of $295 million to $305 million and expects to achieve profitability in 2025, with sustainable annual profitability beginning in 2026.
The PMA for Evolisse Sculpt was submitted to the FDA in Q3 2025, with potential approval anticipated in 2026, and a broader launch of Esteem in Europe is also planned for 2026.
Tatiana Mitchell was welcomed as the new Chief Financial Officer.

Nov 5, 2025, 9:30 PM

Transcript

Evolus Reports Third Quarter 2025 Financial Results

EOLS

Earnings

Guidance Update

Evolus, Inc. reported total net revenue of $69.0 million for the third quarter of 2025, representing a 13% increase over Q3 2024.
This revenue included $63.2 million from global Jeuveau® and $5.7 million from Evolysse™.
The company expects to achieve positive non-GAAP operating income of $5 million to $7 million in Q4 2025 and is on track for sustainable annual profitability beginning in 2026.
Evolus reaffirmed its 2025 net revenue guidance of $295 million to $305 million and non-GAAP operating expenses of $208 million to $213 million.
Cash and cash equivalents stood at $43.5 million as of September 30, 2025.

Nov 5, 2025, 9:12 PM

8-K

Evolus Reports Third Quarter 2025 Financial Results

EOLS

Earnings

Guidance Update

Product Launch

Evolus reported total net revenue of $69.0 million for Q3 2025, representing a 13% increase from Q3 2024, with year-to-date growth of 10%.
Global Jeuveau® net revenue reached $63.2 million in Q3 2025, and Evolysse™ contributed $5.7 million in revenue, marking the strongest hyaluronic acid (HA) filler debut in over a decade.
The company anticipates achieving positive non-GAAP operating income of $5 million to $7 million in Q4 2025, and remains on track for sustainable annual profitability starting in 2026.
Evolus reaffirmed its full-year 2025 net revenue guidance of $295 million to $305 million and non-GAAP operating expenses guidance of $208 million to $213 million.
GAAP loss from operations for Q3 2025 was $11.5 million, while non-GAAP loss from operations was $3.1 million.

Nov 5, 2025, 9:05 PM

Press Release

Evolus Appoints Dr. Benjamin Eskenazi as Lead Consultant for Evolysse™ Filler Launch

EOLS

Product Launch

New Projects/Investments

Evolus, Inc. (NASDAQ: EOLS) has named Dr. Benjamin Eskenazi as lead consultant for the national launch of its new Evolysse™ filler line.
The FDA-approved Evolysse™ Form and Evolysse™ Smooth mark Evolus' entry into the U.S. hyaluronic acid dermal filler market, representing a major technological breakthrough.
Dr. Eskenazi, a board-certified plastic surgeon, will leverage his expertise to support aesthetic providers, demonstrating Evolus' commitment to patient safety and education.
The commercial launch of Evolysse™ Form and Evolysse™ Smooth is scheduled for 2025, with Evolysse™ Sculpt planned for 2026 and Evolysse™ Lips for 2027.

Sep 22, 2025, 1:03 PM

Press Release

Evolus announces positive trial data for Evolysse™ Sculpt

EOLS

Product Launch

New Projects/Investments

Evolus announced positive topline results from a U.S. pivotal study for its Evolysse™ Sculpt injectable hyaluronic acid gel product, demonstrating statistical superiority to Restylane®-Lyft.
The Premarket Approval (PMA) application for Evolysse™ Sculpt has been submitted to the U.S. Food and Drug Administration (FDA), with approval expected in the second half of 2026.
Evolysse™ Sculpt is anticipated to be the flagship brand in the Evolysse™ collection, expanding Evolus's portfolio beyond Jeuveau® and targeting the highest-value segment of the dermal filler market.

Aug 25, 2025, 12:00 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Evolus.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did David Moatazedi say about margins?What are Evolus's strategic priorities?How is Evolus positioned vs competitors?How did Evolus do last quarter?

Let Fintool AI Agent track Evolus's earnings for you

Get instant analysis when filings drop